Published in Health Risk Factor Week, May 16th, 2006
The NDA includes data from a phase III clinical trial as well as data from a sunscreen study, a pharmacokinetic study and a transfer study.
Bio-E-Gel is a low dose estradiol product candidate based on Antares' proprietary Advanced Transdermal Delivery (ATD) gel system and, if approved, will be used to treat moderate-to-severe hot flashes in menopausal women. Antares' ATD system is designed to deliver hormones and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.